Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06341335
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-03-26
Brief Title:
A Study of AK104Placebo Plus AK109Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Sponsor:
Akeso
Organization:
Akeso
Study Overview
Official Title:
A Randomized Double-blind Phase 3 Study Of Cadonilimab AK104 Plus Pulocimab AK109 And Paclitaxel Versus Paclitaxel In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma Who Failed First-line Immunochemotherapy
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This randomized multicenter double-blind phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab AK104 and pulocimab AK109 and paclitaxel compared with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma who failed first-line immunochemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None